Q-omics provides the consensus-scored ADAP1 profile across patient tissues and cancer cell-line models. ADAP1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ADAP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ADAP1 protein abundance shows 26,769 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where ADAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAP1 survival associations across molecular data types. ADAP1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAP1 RNA expression–survival associations across cancer types. High ADAP1 expression shows unfavorable associations in UVM, COAD and UCS, but favorable associations in SKCM, BLCA and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for ADAP1 RNA expression.
This table summarizes ADAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAP1 shows lower tumor expression in KIRC and KIRP and higher tumor expression in STAD, HNSC, BRCA and COAD. The KIRC box plot shows higher ADAP1 RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p < 0.001).
This table shows molecular features associated with ADAP1 in patient tissues and cancer cell lines. In patient samples, ADAP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
